Did 1 acute dose crush autism repetitive behaviors by 43.5%? 🧠💥

#z944 #autism #ocd #neuroscience #brainhealth #pharmacology #neurobiology #behavioralscience #clinicalresearch #medicalscience #brainscience #epilepsyresearch #channelblocker #seizureprevention #neurochemistry

"Here, we examine the specific contribution of the reticular thalamic nucleus (RT)..to ASD-related behavioral deficits using a Cntnap2 knockout mouse model..suppression of RT excitability via Z944, a T-type calcium channel blocker, and via C21 activation of the inhibitory DREADD hM4Di […]

New research confirms Cav3.2 calcium channels in human DRG neurons! This study highlights their sensitivity to the clinical-stage blocker Z944 (but not ABT-639) and significant sex differences in expression. Great news for pain research and exploring Cav3.2 as a therapeutic target! buff.ly/Bz6MDsB

ANOTHER CODE GIVEAWAY!

This the early 2022 Petridisch release, the "space opera", the "misplaced voices" one 😆, "Exhibition on Europa"

truly designed to be an alien transmission

mastered with intent by @angelhairaudio.bsky.social and artworked with consent by @zer0rei.bsky.social

bit.ly/3FylrCC

Inhibition of Caᵥ1.4 channels by Caᵥ3 channel antagonists ML218 and Z944. New study from Jinglang Sun, Amy Lee @utaustin.bsky.social and colleagues: rupress.org/jgp/article/...

@vyy-sf.bsky.social

#MolecularPharmacology #IonChannels

Jinglang Sun, Amy Lee et al. @utaustin.bsky.social show that the commonly used Caᵥ3 T-type channel-selective antagonists, ML218 & Z944, modulate the activity of Caᵥ1.4 L-type channels through a mechanism involving the dihydropyridine-binding site. rupress.org/jgp/article/...

#MolecularPharmacology

🇸🇷 Suriname Nieuws | Dagblad SR

Doorbraak: Epilepsiemedicijn toont potentieel bij behandeling van autisme

https://www.dbsuriname.com/2025/09/05/doorbraak-epilepsiemedicijn-toont-potentieel-bij-behandeling-van-autisme/

Inhibition of CaV1.4 channels by CaV3 channel antagonists ML218 and Z944 https://www.biorxiv.org/content/10.1101/2025.08.30.673144v1

Inhibition of CaV1.4 channels by CaV3 channel antagonists ML218 and Z944 https://www.biorxiv.org/content/10.1101/2025.08.30.673144v1

In @jgp.org, Jinglang Sun, Amy Lee et al. @utaustin.bsky.social show that the commonly used Caᵥ3 T-type channel-selective antagonists, ML218 & Z944, modulate the activity of Caᵥ1.4 L-type channels through a mechanism involving the dihydropyridine-binding site. rupress.org/jgp/article/...

Technology Networks reports that researchers at Stanford found the experimental epilepsy drug Z944 reduced autism-related behaviors in mice by targeting brain circuit activity.

#AccessPress #TechnologyNetworks #AutismResearch #DrugDiscovery #EpilepsyTreatment #Neuroscience

"If the therapeutic effects of targeting the thalamus (with Z944 or other compounds) show improvements in a variety of forms/models of mouse ASD, then that would begin to support the idea of preclinical trials.”

Stanford: autism-like behaviors switched off in mice www.psypost.org/stanford-stu...